ArticleAngewandte Chemie (International ed. in English)2020
A Supramolecular Trap to Increase the Antibacterial Activity of Colistin.
Article in Angewandte Chemie (International ed. in English), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- Lipopolysaccharide hydrolysis-targeting nano-chimeras detoxify endotoxin through specific adsorption and efficient degradation.Nature communications · 2026Article
- Tertiary alkylamine-functionalized polyaspartamides with potent antibacterial activity.Bioactive materials · 2026Article
- Nanodrug Delivery Systems for Direct Clearance or Neutralization of LPS.International journal of nanomedicine · 2025Review
- Therapeutic Interventions forJournal of clinical medicine · 2024Review
- Crafting Stable Antibiotic Nanoparticles via Complex Coacervation of Colistin with Block Copolymers.Biomacromolecules · 2024Article
- In Situ Neutralization and Detoxification of LPS to Attenuate Hyperinflammation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Multifunctional Antibacterial Nanonets Attenuate Inflammatory Responses through Selective Trapping of Endotoxins and Pro-Inflammatory Cytokines.Advanced healthcare materials · 2023Article
- Colistin Use in European Livestock: Veterinary Field Data on Trends and Perspectives for Further Reduction.Veterinary sciences · 2022Article
- Combatting Antibiotic Resistance Using Supramolecular Assemblies.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Supramolecular Bait to Trigger Non-Equilibrium Co-Assembly and Clearance of Aβ42.Angewandte Chemie (International ed. in English) · 2021Article
- A Supramolecular Trap to Increase the Antibacterial Activity of Colistin.Angewandte Chemie (International ed. in English) · 2020Article
- Primary Amine Modified Gold Nanodots Regulate Macrophage Function and Antioxidant Response: Potential Therapeutics Targeting of Nrf2.International journal of nanomedicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
A strong interaction between colistin, a last-resort antibiotic of the polymyxin family, and free lipopolysaccharide (LPS, also referred to as endotoxin), released from the Gram-negative bacterial (GNB) outer membrane (OM), has been identified that can decrease the antibacterial efficacy of colistin, potentially increasing the dose of this antibiotic required for treatment. The competition between LPS in the GNB OM and free LPS for the interaction with colistin was prevented by using a supramolecular trap to capture free LPS. The supramolecular trap, fabricated from a subnanometer gold nanosheet with methyl motifs (SAuM), blocks lipid A, preventing the interaction between lipid A and colistin. This can minimize endotoxemia and maximize the antibacterial efficacy of colistin, enabling colistin to be used at lower doses. Thus, the potential crisis of colistin resistance could be avoided.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.